AlphaQuest LLC Has $399,000 Position in Medpace Holdings, Inc. $MEDP

Key Points

• AlphaQuest LLC increased its position in Medpace Holdings by 292.8% in the first quarter, owning 1,308 shares valued at $399,000.
• Analysts recently revised their price targets for Medpace; Deutsche Bank raised its target to $430, while Cowen downgraded it to a "sell" rating.
• Medpace reported a quarterly revenue of $603.31 million, exceeding expectations, and set a fiscal year 2025 EPS guidance of 13.760-14.530.

AlphaQuest LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 292.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,308 shares of the company's stock after purchasing an additional 975 shares during the quarter. AlphaQuest LLC's holdings in Medpace were worth $399,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. Brooklyn Investment Group boosted its holdings in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. Whittier Trust Co. lifted its stake in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the last quarter. Colonial Trust Co SC lifted its stake in Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after buying an additional 105 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Medpace in the first quarter valued at approximately $60,000. Finally, Assetmark Inc. lifted its stake in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research reports. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and upped their price target for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. TD Cowen reaffirmed a "sell" rating and set a $366.00 price objective (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Cowen downgraded shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, Mizuho increased their price objective on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and an average price target of $406.60.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares of the company's stock, valued at $4,654,350. The trade was a 22.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the sale, the vice president directly owned 57,500 shares in the company, valued at $25,883,050. This represents a 11.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 115,070 shares of company stock worth $52,085,751 over the last ninety days. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Up 0.5%

Shares of MEDP traded up $2.57 during mid-day trading on Friday, hitting $475.51. The stock had a trading volume of 408,536 shares, compared to its average volume of 341,743. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The company's fifty day simple moving average is $395.75 and its two-hundred day simple moving average is $339.38. The company has a market cap of $13.36 billion, a PE ratio of 35.35, a PEG ratio of 2.99 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the previous year, the firm posted $2.75 EPS. The business's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.